Serum osteopontin predicts the response to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma

[1]  Yufeng Liu,et al.  Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy. , 2023, Journal of hepatology.

[2]  A. Zhu,et al.  Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. , 2022, The Lancet. Oncology.

[3]  A. Zhu,et al.  Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma , 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  Lixin Sun,et al.  Osteopontin promotes hepatocellular carcinoma progression through inducing JAK2/STAT3/NOX1-mediated ROS production , 2022, Cell Death & Disease.

[5]  Y. Hiasa,et al.  Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective study , 2022, Hepatology International.

[6]  Y. Imai,et al.  Interleukin-6 Is a Circulating Prognostic Biomarker for Hepatocellular Carcinoma Patients Treated with Combined Immunotherapy , 2022, Cancers.

[7]  M. Kudo,et al.  Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. , 2021, Journal of hepatology.

[8]  Y. Hirooka,et al.  Early Changes in Alpha-Fetoprotein Are a Useful Predictor of Efficacy of Atezolizumab plus Bevacizumab Treatment in Patients with Advanced Hepatocellular Carcinoma , 2021, Oncology.

[9]  J. Bruix,et al.  BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update. , 2021, Journal of hepatology.

[10]  M. Ebert,et al.  Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score. , 2021, Journal of hepatology.

[11]  H. Seno,et al.  Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictive Marker of Response to Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma , 2021, Current oncology.

[12]  Y. Hiasa,et al.  Impact of modified albumin–bilirubin grade on survival in patients with HCC who received lenvatinib , 2021, Scientific Reports.

[13]  T. Murakami,et al.  Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update , 2021, Liver Cancer.

[14]  J. Ferlay,et al.  Cancer statistics for the year 2020: An overview , 2021, International journal of cancer.

[15]  Yulei N. Wang,et al.  Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. , 2020, The New England journal of medicine.

[16]  F. Montecucco,et al.  Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer , 2019, Clinical & Experimental Metastasis.

[17]  M. Hung,et al.  Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade , 2019, Gut.

[18]  M. Kudo,et al.  Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. , 2019, The Lancet. Oncology.

[19]  M. Kudo,et al.  Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial , 2018, The Lancet.

[20]  M. Abecassis,et al.  AASLD guidelines for the treatment of hepatocellular carcinoma , 2018, Hepatology.

[21]  M. Kudo,et al.  Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function , 2017, Liver Cancer.

[22]  Masatoshi Kudo,et al.  Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial , 2017, The Lancet.

[23]  B. Sangro,et al.  Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Ziding Feng,et al.  Identification of osteopontin as a novel marker for early hepatocellular carcinoma , 2012, Hepatology.

[25]  Riccardo Lencioni,et al.  Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma , 2010, Seminars in liver disease.

[26]  D. Zhang,et al.  Osteopontin induces angiogenesis through activation of PI3K/AKT and ERK1/2 in endothelial cells , 2009, Oncogene.

[27]  D. Batlle,et al.  Hypoxia and high glucose cause exaggerated mesangial cell growth and collagen synthesis: role of osteopontin. , 2001, American journal of physiology. Renal physiology.

[28]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[29]  G. Rodan,et al.  Transcriptional regulation of osteopontin production in rat osteoblast- like cells by parathyroid hormone , 1989, The Journal of cell biology.

[30]  P. Mahadevan,et al.  An overview , 2007, Journal of Biosciences.

[31]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[32]  D. Woodfield.  Hepatocellular carcinoma. , 1986, The New Zealand medical journal.